Business
Xtant Medical Reports First Quarter 2025 Financial Results
Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today reported financial and operating results for the first quarter ended March 31, 2025.
About this update from Xtant Medical Holdings, Inc.
[{"type":"text","content":"Revenue Increases 18% Year-over-Year","length":36,"tagName":"p","attribs":{}},{"type":"text","content":"Delivers Positive Net Income and $1.3 Million in Operating Cash Flow","length":68,"tagName":"p","attribs":{}},{"type":"text","content":"Increases 2025 Revenue Guidance to $127 Million to $131 Million ","length":63,"tagName":"p","attribs":{}},{"type":"text","content":"BELGRADE, Mont., May 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today reported financial and operating results for the first quarter ended March 31, 2025.","length":321,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Financial Highlights","length":39,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $32.9 million, up 18%, compared to the prior year quarter","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross margin of 61.5% compared to 62.1% for the prior year quarter","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Net income of $58,000 compared to a net loss of $4.4 million in the prior year quarter","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted EBITDA of $3.0 million compared to an adjusted EBITDA loss of $1.0 million in the prior year quarter","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash from operations of $1.3 million compared to cash used in operations of $5.8 million in the prior year quarter","length":114,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":443,"olType":false},{"type":"text","content":"Recent Business Highlights ","length":26,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Launched Trivium™, a premium, next-generation demineralized bone matrix (DBM) allograft designed to elevate the standard of care in bone grafting procedures","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced completion of a secondary private sale of existing shares by OrbiMed Advisors LLC ("OrbiMed") to several existing and new stockholders, led by Nantahala Capital Management LLC ("Nantahala")","length":219,"tagName":"p"}]},{"val":[{"type":"text","content":"Terminated investor rights agreement with OrbiM...